Discovery of a Potent Dihydrooxadiazole Series of Non-ATP-Competitive MK2 (MAPKAPK2) Inhibitors.

Abstract

Inhibition of MK2 has been shown to offer advantages over that of p38 MAPK in the development of cures for inflammatory diseases such as arthritis. P38 MAPK knockout in mice was lethal, whereas MK2-null mice demonstrated strong inhibition of disease progression in collagen-induced arthritis and appeared normal and viable. However, it is challenging to… (More)
DOI: 10.1021/ml200238g

Topics

Cite this paper

@article{Qin2012DiscoveryOA, title={Discovery of a Potent Dihydrooxadiazole Series of Non-ATP-Competitive MK2 (MAPKAPK2) Inhibitors.}, author={Jun Qin and Pawan K Dhondi and Xianhai Huang and Robert G Aslanian and James D. Fossetta and Fang Tian and Daniel J. Lundell and Anandan Palani}, journal={ACS medicinal chemistry letters}, year={2012}, volume={3 2}, pages={100-5} }